Premium
R‐DA‐EPOCH improves the outcome over that of the R‐CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high IPI , but not for double expressor lymphoma
Author(s) -
Xu W.,
Zhang X.,
Liang J.,
Wang L.,
Zhu H.,
Wu W.,
Fan L.,
Li J.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_82
Subject(s) - vincristine , epoch (astronomy) , medicine , rituximab , regimen , chop , gastroenterology , prednisone , cyclophosphamide , etoposide , diffuse large b cell lymphoma , surgery , lymphoma , chemotherapy , oncology , stars , physics , astronomy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom